CDT earnings analysis
What we found in CDT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment results, or quantitative guidance, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed from the filing text provided. The principal disclosed negative is that disclosure controls remained ineffective as of June 30, 2026 because previously identified material weaknesses were not remediated. Litigation also remains material, including an approximately $7 million judgment against CPL that Strand is seeking to recover from CDT.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No unreported equity sales or repurchases
- The company reported no unregistered equity sales during the quarter ended June 30, 2026 and no common-stock repurchases during the six months ended June 30, 2026.
- Management sees limited routine litigation impact
- Management stated it does not expect pending ordinary-course claims to materially affect results, financial position, or cash flows, although the company disclosed a December 16, 2025 judgment against CPL of approximately $7 million plus interest and a portion of costs.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weaknesses remain unresolved
- Disclosure controls and procedures were concluded to be ineffective as of the fiscal quarter ended June 30, 2026, because previously identified material weaknesses had not been remediated.
- Potential $7 million litigation exposure
- Strand is seeking recovery from CDT of a December 16, 2025 High Court judgment against CPL for approximately $7 million, plus interest and a fraction of Strand’s costs; CDT denies liability.
- Patent ownership dispute remains pending
- The company disclosed a patent-entitlement proceeding initiated by St George Street Capital on December 18, 2024 concerning patent application PCT/IB2022/00775. The company disputes the claims and states that further updates will follow UK IPO notification.
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the supplied 10-Q text. The filing does not provide operating forecasts or explicit guidance.
The filing reads worse than the one before it.
What came before.
- 10-Q · July 15, 2026
- CDT Equity Inc. reported a diluted EPS of $45,647.11 for Q1 2026, a remarkable turnaround from prior losses, although revenue remains undisclosed. Operating expenses remained stable with a slight decrease in R&D costs…
- 10-K · April 15, 2026
- CDT Equity (CDT) has repositioned as a lean, AI- and solid-form-driven drug-repositioning platform after licensing AZD1656, AZD5658 and AZD5904 from AstraZeneca and building related partnerships (Sarborg and Manoira).…
- 10-Q · August 14, 2025
- CDT Equity (formerly Conduit Pharmaceuticals) reported a Q2 net loss of $6,028 (three months) and GAAP EPS of $(5.46), driven by a ramp in R&D and continued G&A. Liquidity improved materially — cash rose to $3,332 from…
- 10-Q · May 15, 2025
- For the quarter ended March 31, 2025 Conduit Pharmaceuticals reported a net loss of $(5,146) (three months ended March 31, 2025) versus $(3,552) in the prior-year quarter, with basic and diluted net loss per share of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CDT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever